IGF-1 LR3 is banned by WADA. Do not use if you have active cancer, are in remission, or have a strong family history of hormone-sensitive cancers — the IGF-1R mechanism can accelerate existing cancer cell growth.
COMPOUND PROFILE · PEPPERLEDGER
IGF-1 LR3
Type
Synthetic analog of human IGF-1 with N-terminal Arg-Lys extension and Glu→Arg substitution at position 3
~20–30 hours — dramatically longer than native IGF-1 (~12–15 minutes) due to ~1000-fold reduced IGFBP binding
Most studied use
Muscle hypertrophy · Fat loss · Recovery · Often used after or alongside GH secretagogue cycles
Regulatory status
Not FDA-approved for human use · Used in cell culture research · WADA-banned · Research chemical
Human evidence
Very limited — no controlled trials in healthy adults for body composition; primary evidence from GH deficiency research and animal models
Preclinical evidence
Strong — well-characterized IGF-1R mechanism; extensive animal data on muscle hypertrophy and fat loss
EDUCATIONAL TOOL — NOT MEDICAL ADVICE
What is IGF-1 LR3?
IGF-1 LR3 is a synthetic analog of insulin-like growth factor 1 (IGF-1) — the primary downstream mediator of growth hormone's anabolic effects. Where GH secretagogues (CJC-1295, ipamorelin, GHRP-2) work by stimulating your pituitary to release GH, which then signals your liver to produce IGF-1, IGF-1 LR3 skips the entire upstream signaling chain and directly activates IGF-1 receptors throughout the body. The result is potent, direct anabolic signaling — protein synthesis in muscle, fat cell breakdown, connective tissue support — without the intermediary steps.
The LR3 modification makes it dramatically more potent and longer-lasting than native IGF-1. Native IGF-1 has a half-life of roughly 12–15 minutes in plasma because it's rapidly bound by IGF-binding proteins (IGFBPs). The LR3 modification reduces IGFBP binding affinity by approximately 1000-fold, extending the half-life to 20–30 hours.
The risks require honest engagement. IGF-1 promotes cell growth broadly — not selectively in muscle. It stimulates IGF-1 receptors on all tissues, including any cancer cells that express IGF-1R. This is a meaningful concern for anyone with undiagnosed cancer or significant cancer risk. Additional risks: hypoglycemia (IGF-1 has insulin-like effects on glucose), organ growth (heart, liver, kidneys with prolonged use), and acromegalic changes with very long protocols.
How it works
IGF-1 Receptor Activation and mTOR
IGF-1 LR3 binds the IGF-1 receptor (IGF-1R) — a receptor tyrosine kinase expressed in virtually all tissues. IGF-1R activation triggers PI3K/Akt/mTOR signaling (protein synthesis, cell growth, survival) and MAPK/ERK signaling (proliferation, differentiation). In muscle: mTOR activation drives ribosomal protein synthesis and muscle fiber growth; satellite cell proliferation enables true hyperplasia rather than just hypertrophy.
The LR3 Modification — Why It's Different
Approximately 98% of circulating native IGF-1 is IGFBP-bound. The LR3 modification reduces IGFBP binding ~1000-fold — IGF-1 LR3 remains bioavailable in plasma for 20–30 hours rather than minutes. This is the pharmacological basis for its potency.
Hypoglycemia Risk
IGF-1 has structural homology with insulin and activates insulin receptors at high concentrations, producing insulin-like effects on glucose uptake. IGF-1 LR3's long half-life means this hypoglycemic risk is sustained for up to 30 hours after injection. Users must eat carbohydrates within 20–30 minutes of injection and have fast-acting glucose available.
What the research shows
HUMAN AND MECHANISTIC EVIDENCE
STUDYJournal of Molecular Endocrinology · 1992
Long R3 IGF-1 vs native IGF-1 — binding and bioactivity comparison
Francis GL, Ross M, Ballard FJ et al.
Established the LR3 modification's effect on IGFBP binding (~1000-fold reduction) and receptor affinity. Foundation for understanding why IGF-1 LR3 is more potent and longer-lasting than native IGF-1.
IGF-1 and muscle hypertrophy — systematic review of GH/IGF-1 axis interventions
Yarrow JF, White LJ, McCoy SC, Borst SE.
Systematic review of GH and IGF-1 interventions in healthy adults. GH increases IGF-1 and lean mass; the independent contribution of IGF-1 vs. GH is difficult to separate. Direct IGF-1 LR3 human trials in healthy adults are absent.
IGF-1 promotes cell growth broadly. It does not cause cancer de novo — but it can accelerate the growth of existing cancer cells that express IGF-1R, which virtually all do. Do not use if you have active cancer, are in remission, have a strong family history of hormone-sensitive cancers (breast, prostate, colon), elevated PSA, or are over 60 with high cancer background risk without oncology clearance. This is a mechanistically grounded concern, not theoretical.
—Significant muscle fullness and vascularity increase — often noticeable within days; muscle cells take up more nutrients and glycogen
—Accelerated muscle growth on consistent training — faster hypertrophy than GH secretagogue-only protocols
—Fat loss alongside muscle gain — simultaneous body composition improvement is the primary reported benefit
—Hypoglycemia in hours post-injection — the most consistently noted risk; eating carbohydrates shortly after injection generally avoids it
—Joint and connective tissue improvement — collagen synthesis effects similar to BPC-157
—Duration limitation: most experienced users limit cycles to 4–6 weeks due to receptor desensitization and organ growth concerns
Common misconceptions
"IGF-1 LR3 causes cancer."
REALITY
IGF-1 LR3 does not cause cancer de novo. The concern is that elevated IGF-1 can accelerate growth of existing cancer cells that express IGF-1R. This is a meaningful risk for someone with undiagnosed cancer or significant cancer risk — not a claim that it causes cancer to develop in cancer-free individuals.
"IGF-1 LR3 is just stronger GH."
REALITY
GH works by signaling the liver to produce IGF-1, which then acts systemically. IGF-1 LR3 bypasses this entirely and directly activates IGF-1 receptors throughout the body at supraphysiologic levels for 20–30 hours. Direct receptor activation at this level is categorically different from even the strongest GH secretagogue protocols.
"You can run IGF-1 LR3 indefinitely."
REALITY
Prolonged continuous IGF-1R stimulation drives organ growth — heart, liver, and kidneys can enlarge with chronic supraphysiologic IGF-1 exposure. Short cycles (4–6 weeks) with breaks are standard practice to avoid cumulative organ growth effects. This is one of the features of acromegaly.
CJC-1295 + Ipamorelin elevate IGF-1 indirectly via GH stimulation — within physiological ranges with a much cleaner safety profile. For most users, optimizing the GH secretagogue stack before considering direct IGF-1R activation is the appropriate progression.
RECONSTITUTION CALCULATOR
EDUCATIONAL TOOL — NOT MEDICAL ADVICE · VERIFY WITH YOUR CLINICIAN
AI COACH PREVIEW
I want to run IGF-1 LR3 after my CJC + ipamorelin cycle. What should I watch for?
Running IGF-1 LR3 after a GH secretagogue cycle is the standard progression — you've been elevating GH and therefore IGF-1 indirectly; now you're considering direct IGF-1R activation. Here's what matters most. Hypoglycemia is the primary acute risk and the one that catches people off guard most often. IGF-1 LR3's 20–30 hour half-life means the insulin-like effect on glucose uptake persists well after injection — not just in the first hour. Practical protocol: never inject fasted. Eat within 20–30 minutes of injection, carbohydrates specifically. Keep fast-acting glucose available (glucose tablets, juice) for the first 24 hours after each injection, especially in week 1 while you're establishing how your body responds. If you feel shaky, sweaty, or confused after injection — that's hypoglycemia, treat immediately. Dose: start at 20 mcg. Not 50, not 100 — 20. This is a potent compound with a 20–30 hour half-life. The first injection tells you a lot about your individual sensitivity. If 20 mcg is well-tolerated with clear effects in training, you can assess whether 30–50 mcg makes sense. Cycle length: 4–6 weeks maximum. IGF-1R desensitization and organ growth concerns make extended cycles inadvisable. The off-period should be at least as long as the cycle. Cancer risk disclosure: before you start — if there's any personal or family history of hormone-sensitive cancer, or if you haven't had recent bloodwork that would flag any concerning markers, that warrants a conversation with a physician first. IGF-1 LR3 is not appropriate for people with active cancer, in remission, or with elevated PSA without oncology clearance. What does your current CJC + ipamorelin protocol look like, and what's the primary goal — hypertrophy, recomposition, or both?
CONTINUE IN THE APP
Open PepperLedger to track your IGF-1 protocol →
Free to join. No credit card. Ask the Coach about your IGF-1 LR3 protocol once you're in.
Free to join · No credit card · 23-day Pro trial included